Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR -Mutant Chronic Myeloproliferative Neoplasms.

Autor: Handlos Grauslund J; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Jørgensen NG; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Klausen U; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Weis-Banke SE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., El Fassi D; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.; Department of Medicine, Copenhagen University, Copenhagen, Denmark., Schöllkopf C; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Clausen MB; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Gjerdrum LMR; Department of Pathology, Zealand University Hospital, Roskilde, Denmark., Breinholt MF; Department of Pathology, Copenhagen University Hospital, Herlev, Denmark., Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Koschmieder S; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany., Chatain N; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany., Novotny GW; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Petersen J; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Institute for Immunology and Microbiology, Copenhagen University, Copenhagen, Denmark.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Feb 26; Vol. 11, pp. 637420. Date of Electronic Publication: 2021 Feb 26 (Print Publication: 2021).

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.

Autor: Jørgensen NG; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Klausen U; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Grauslund JH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Helleberg C; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Aagaard TG; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Do TH; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Ahmad SM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Olsen LR; Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark., Klausen TW; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Breinholt MF; Department of Pathology, Copenhagen University Hospital, Herlev, Denmark., Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Knudsen LM; Department of Hematology, Copenhagen University Hospital, Herlev, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Nov 09; Vol. 11, pp. 595035. Date of Electronic Publication: 2020 Nov 09 (Print Publication: 2020).

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Autor: Jørgensen NG; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Ahmad SM; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Abildgaard N; Department of Hematology, University Hospital Odense, Odense, Denmark., Straten PT; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Svane IM; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark;; Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Andersen MH; Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark., Knudsen LM; Department of Hematology, Herlev and Gentofte Hospital, Herlev, Denmark.

Publikováno v: Stem cell investigation [Stem Cell Investig] 2016 Dec 23; Vol. 3, pp. 95. Date of Electronic Publication: 2016 Dec 23 (Print Publication: 2016).